

WACKER – Accelerating Proven Successes

Wacker Chemie AG

July, 2024

Disclaimer

The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.



Front page: WACKER has reached a milestone on June 3rd by opening an mRNA competence center at its biotech site in Halle (Saale), Germany. The new facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA), such as anti-Covid mRNA vaccines.

WACKER: At a Glance

Facts & Figures

€6.4bn 16,378

Sales in 2023 Employees

€824m 27


EBITDA in 2023 Production Sites

13% 22

EBITDA margin Technical Centers

in 2023

4 Business Scientific Segments 45 collaborations





SILICONES: At a Glance



The Fully Integrated Specialty Supplier


- Customer's first choice for innovative and customized solutions in all regions
- Benchmark production and service close to customers



Sustainability Pull For Specialty Solutions

- Silicones with unmatched performance & versatility
- Smart Construction, E-mobility, Renewable Energy, Sustainable Raw Materials

Financial Performance



POLYMERS: At a Glance



VAE/DPP¹ Capacity Leader with World Class Tandems


- Customized service to key accounts and local champions in the regions
- Addressing individual market requirements
- Innovation and in-depth formulating expertise



Pull from Sustainability and Smart Construction

- Performance-based substitution in construction and binder markets
- Lead transformation to high construction standards
- Sustainability driven "plastic to paper" trend

Financial Performance



1) DPP = <u>Dispersible Polymer Powders</u> VAE= <u>Vinyl acetate-ethylene</u>



BIOSOLUTIONS: At a Glance



Fast Growing Biotechnology Business


- Leading microbial manufacturing technologies
- Jump-started into advanced medicines (mRNA, pDNA)
- Successfully acquired and integrated biotech sites



Pull from Advanced Medicine and Clean Food

- CDMO outsourcing trend with high potential
- Consumer focus on health and well being trend

Financial Performance





POLYSILICON: At a Glance



Leadership in High End Applications Established


- ▶ #1 Position in Semi
- Market leader for high-end n-type solar
- Strong long-standing cooperation with customers



Pull from Rapidly Growing Semi and Solar Markets

- Strong growing chip demand
- High efficiency modules require high quality polysilicon
- Best-in-class sustainability & Regional differentiation

Financial Performance





Committed to Achieve 2030 Group Targets



Faster Growth, Bolder Moves, High Profitability

Sales: >€10bn

▶ EBITDA Margin: >20%

▶ Volume/Mix CAGR: 1.5 – 2x historic

▶ ROCE: 2x Cost of Capital



Strategic Growth Projects


▶ SILICONES: Specialties

▶ POLYMERS: Tandems (VAE+DPP)

BIOSOLUTIONS: Biologics

▶ POLYSILICON: Semi

Chemicals¹ Financial KPIs



1) Chemicals = SILICONES + POLYMERS



2030 Targets - Capital Allocation Priorities

GROWTH

CapEx and M&A

High-Return Growth CapEx

- Accelerate chemical capacities in all regions, diversified portfolio of downstream projects
- ▶ Early-stage assets, create synergies in BIOSOLUTIONS; strengthen market position

1

SHAREHOLDER RETURNS

Dividends

Strong Commitment to Shareholders

- Continued policy of ~50% payout of net income from continuing operations
- ▶ For FY 2023, dividend of €3 per share in-line with policy

2

PENSIONS

Reform

Initiatives Underway to Reduce Pension Deficit

Modernization of our system to a fully funded defined contribution system, relevant for all new employees and everybody willing to switch over to it



Ambitious Sustainability Targets for 2030



Value Up

100% Products meet sustainability criteria



Footprint Down

50% Reduction in absolute GHG¹ emissions (vs. 2020)

15% Reduction in specific water withdrawal (vs. 2020)

15% Reduction in specific energy consumption (vs. 2020)

Accidents



Collaboration Beyond

100% Key suppliers meet sustainability standards

25% Reduction in absolute upstream GHG emissions (vs. 2020)

Extend World-class "Verbund" sites and circular economy





Clear Commitment to 1.5°C Paris Agreement

Net Zero

1) GHG = Greenhouse gas



Progress Made on Achieving Ambitious Group Sustainability Targets

	2020	2021	2022	2023	2030 Target
Net Zero	100%	93%	87%	72%	100% reduction by 2045
Value Up					
Sustainable products	83%	89%	90%	94%	100% of products meet defined sustainability criteria
Diversity: Woman in management	17%	19%	21%	21%	33% of management positions held by woman
Regionalization: Management	27%	29%	30%	32%	50% management positions outside Germany
Footprint Down					
CO ₂ e (Scope 1+2) emissions	100%	101%	89%	86%	50% reduction in absolute CO ₂ e emissions
Energy consumption	100%	98%	99%	103%	15% reduction in specific energy consumption
Water withdrawal	100%	98%	102%	104%	15% reduction in specific water withdrawal
Collaboration Beyond					
CO ₂ e (Scope 3) emissions	100%	86%	80%	62%	25% reduction in absolute CO ₂ e emissions
Sustainable supply chain	57%	60%	72%	79%	100% of key suppliers meet defined TfS criteria
Health & Safety					
Chemical accidents with missed workdays ¹	3	4	10	2	0 days – reoccurring annual target
Severe process safety incidents	1	3	3	0	0 incidents – reoccurring annual target

1) 2023: incidents per million work hours: 3.3 Target: <2



Appendix Q2 2024 Results


In €m	Q2 2024	Q2 2023	% YoY
Sales	1,468	1,753	-16%
EBITDA reported	160	256	-37%
EBITDA-Margin	10.9%	14.6%	
EBIT	43	153	-72%
EBIT-Margin	2.9%	8.7%	
Net income for the period	35	119	-71%
EPS	0.58	2.38	-75%
CapEx	177	145	22%
Net Cashflow	-179	-99	82%
Net Debt	661	270	145%




Appendix Q2 2024 Results – Breakdown by Business


	Sales				EBITDA				EBITDA Margin (%)				
In €m / %	Q2/24	Q2/23	% YoY	Q1/24	% QoQ	Q2/24	Q2/23	% YoY	Q1/24	% QoQ	Q2/24	Q2/23	Q1/24
Chemicals	1,108	1,115	-1%	1,083	2%	149	128	17%	137	9%	13.4	11.4	12.6
SILICONES	719	699	3%	710	1%	90	52	73%	81	11%	12.6	7.4	11.4
POLYMERS	389	417	-7%	372	5%	59	76	-23%	56	5%	15.0	18.1	15.0
BIOSOLUTIONS	98	91	8%	72	37%	1	-1	-	5	-	1.1	-0.6	6.4
POLYSILICON	232	513	-55%	300	-23%	55	156	-65%	43	27%	23.8	30.5	14.5
Others	34	38	-10%	39	-13%	-45	-27	-	-13	-	-	-	-
Consolidation	-4	-4	-	-4	-	0	-1	-	0	-	-	-	-
WACKER Group	1,468	1,753	-16%	1,490	-1%	160	256	-37%	172	-7%	10.9	14.6	11.6

Appendix Key Raw Materials, Power and Gas











Appendix

Guidance: FY EBITDA Now Expected in Upper Half of Range

In €m	FY 2023	Outlook 2024
Sales	6,402	€6,000 – 6,500m
EBITDA	824	€600 – 800m
EBITDA margin (%)	12.9	Substantially lower than last year
Net cash flow	166	Negative, substantially lower than last year
CapEx	710	Slightly lower than last year
Net Debt	84	Higher than last year
Net Income	327	Substantially lower than last year
Depreciation	419	Around €450m
ROCE (%)	6.9	Substantially lower than last year
Tax Rate (%)	15.4	Around 20%

WACKER: Issuer, Contact and Additional Information

Issuer and Contact

INVESTOR RELATIONS CONTACTS

Joerg Hoffmann, CFA

Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com

Scott McCollister

Tel. +49 89 6279 1560 | scott.mccollister@wacker.com

Wacker Chemie AG

Gisela-Stein-Straße 1, D-81671 Munich investor.relations@wacker.com

Additional Information



ISIN DE000WCH8881 WKN WCH888

Deutsche Börse WCH

Financial Calendar

09/18+19/24 CMD Burghausen 10/29/24 Q3 2024 Results

Publications









CUSTOMER MAGAZINE **FACTBOOK**

ANNUAL REPORT & ESG DISCLOSURES

SQUARE APP

